Late-StageResearch compound

Mazdutide (IBI362)

GLP-1/glucagon dual agonist, registered in China

Telegram
Mazdutide (IBI362) vial

WHAT IS MAZDUTIDE (IBI362)?

Detailed overview

Mazdutide (IBI362, LY3305677) is an oxyntomodulin-based dual GLP-1/glucagon receptor agonist co-developed by Innovent Biologics and Eli Lilly. It received Chinese regulatory acceptance for obesity in late 2024, the first dual agonist approved there.

Type

GLP-1 / glucagon dual agonist

Structure

Oxyntomodulin-based analog

Status

Approved in China (2024)

Route

SC, heti 1×

Storage

2–8°C

Source

Placeholder, image later

Metabolic support

Glucose and lipid metabolism shift favorably: insulin sensitivity improves, glycemic swings and HbA1c drop, while LDL and triglycerides normalize. Body composition refines, fat mass decreases, lean mass is preserved or grows. Appetite is regulated both centrally and peripherally (GLP-1 / GIP / glucagon pathways), so caloric intake settles into a sustainable range without constant willpower. Energy expenditure and thermogenesis rise modestly.

Data console

Lab data

/lab/molecular-data.jsonLIVE
> ClassificationGLP-1 / glucagon dual agonist
> StructureOxyntomodulin-based analog
> Molecular weightN/A
> Target area-
> Storage2–8°C
> Stability~30 days reconstituted

Research indications

Investigated uses and mechanisms

Weight regulation

Reduced appetite and increased energy expenditure via GLP-1 / GIP / glucagon agonism.

Type 2 diabetes

Improved insulin sensitivity and HbA1c reduction in clinical trials.

Cardiometabolic profile

Favorable shifts in lipid profile and blood pressure.

Reconstitution

How to prepare, step by step

Important

Sterile technique required. Use bacteriostatic water (BAC) only. Never distilled or tap water.

  1. 01

    Remove the vial and bacteriostatic water (BAC) from refrigeration; let them reach room temp for 5 minutes.

  2. 02

    Wipe both vial stoppers with an alcohol swab.

  3. 03

    Draw 1 ml of BAC water into a sterile syringe (typical for the 9 mg vial).

  4. 04

    Inject slowly down the side of the vial, do NOT spray directly onto the peptide powder.

  5. 05

    Swirl gently in a circular motion until dissolved (~30 s), do not shake.

  6. 06

    Wait for the solution to become clear. If sediment or discoloration appears, discard it.

  7. 07

    Label the vial with reconstitution date and concentration.

  8. 08

    Store at 2–8 °C, protected from light. Inspect visually before each use.

Quality indicators

How to recognize a pure peptide

Purity markers

3

  • Clear oil

    Clear or slightly yellow (MCT/sesame/castor oil), particle-free.

  • Vial integrity

    Glass intact, rubber stopper undamaged, aluminum crimp tight.

  • Label + COA

    Manufacturer + LOT + expiry legible; independent HPLC analysis on active content.

Use caution

1

  • BA/BB carrier blend

    Excessive benzyl alcohol (>3%) raises PIP risk; verify with UGL manufacturers.

Do not use

2

  • Cloudiness / sediment

    Floating particles, cloudiness, or sediment = HARD NO.

  • Damaged glass / stopper

    Cracked vial or loose stopper, sterility compromised.

Interactions & stacks

What to combine and what to avoid

Retatrutide

Synergistic

Triple incretin agonist: metabolic health and weight loss

Tirzepatide

Synergistic

Dual GIP/GLP-1 agonist: weight & glucose control

Berberine

Synergistic

Insulin sensitivity + GLP-1 effects combine well.

Vitamin C / Zinc / B-complex

Synergistic

Supports collagen synthesis and antioxidant capacity.

Metformin

Complementary

Many clinical protocols combine them, supervision advised.

Caffeine

Requires timing

Compatible with morning dosing; avoid late-day stacking.

NSAIDs (Ibuprofen, ASA)

Use caution

Long-term concurrent use may blunt regenerative effects.

Alcohol

Avoid

Reduces recovery and increases side-effect risk.

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Nausea, headache, especially during titration
  • Appetite and bowel-motility shifts
  • Local skin reaction at injection site
  • Transient blood-sugar variability (esp. in diabetics)
  • Mild heart-rate increase
  • PIP (post-injection pain) – especially propionate, trenbolone-ace, or high-BA blends
  • Injection-site reaction: lumps, redness, warmth, tenderness

Contraindications · 5

  • Pregnancy and breastfeeding
  • Active malignancy
  • Known allergy to the peptide or its components
  • Severe hepatic or renal impairment (medical consultation required)
  • Age under 18

Related Peptides

Same therapeutic category

Studies

Related research and clinical findings

Research
N Engl J Med. 2025;392(22):2215-2225. · 2025

Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.

Ji L, Jiang H, Bi Y, Li H, Tian J

Mazdutide 9 mg/week produced 14.4% body weight reduction over 32 weeks vs placebo.

PMID: 40421736Open

Telegram

Have a question about Mazdutide (IBI362)?

Reach out to an advisor on Telegram. We can help you find the right peptide.

Telegram
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: June 2, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.